Metformin is safe to use during pregnancy to manage diabetes, with no long-term adverse effects on the children born and their mothers for at least 11 years after childbirth, according to research presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass. This is the first study to look at longer term effects of metformin use during pregnancy.
Among transgender and gender-diverse adults whose gender identity is nonbinary—not exclusively male or female—and who choose low-dose hormone treatment, most prefer to continue testosterone therapy at lower-than-recommended doses after at least six months of treatment, a new study finds. The study will be presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Vitamin D tests certified by the U.S. Centers for Disease Control and Prevention (CDC) Clinical Standardization Programs (CSP) are well calibrated overall, according to a new study presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass. However, the researchers found some inaccuracies among the assays studied.
Exposure to increased neighborhood violence has the power to change the glucocorticoid receptor (GR) for the stress hormone, cortisol, which may influence the aggressiveness of lung cancer, according to data presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
High insulin levels contribute to worse outcomes for Black women compared to white women who have an aggressive form of breast cancer called triple-negative breast cancer, according to a study presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Older women with low bone density are more likely to experience their first hip fracture in their 60s compared to older ages, according to research being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Men who illicitly used steroids to boost muscle size and physical performance and have stopped in the past year have impaired sexual function compared with men currently using steroids, according to a study being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
A novel male contraceptive gel combining two hormones, segesterone acetate (named Nestorone) and testosterone, suppresses sperm production faster than similar experimental hormone-based methods for male birth control, according to a new study.
Women experiencing moderate-to-severe vasomotor symptoms face a three times greater risk for metabolic-dysfunction-associated steatotic liver disease (MASLD) compared to those with mild symptom severity, according to research being presented Monday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Almost one out of five breast cancer survivors may experience weight gain of more than 10%, suggests a study presented Monday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass. A number of factors are associated with excessive weight gain, the researchers found.
A new “armored” form of CAR T cell therapy may be able to help patients with non-Hodgkin lymphoma whose cancers do not respond to currently available CAR T cell therapies. The Phase I clinical trial was presented at the 2024 ASCO Annual Meeting.
Medications for type 2 diabetes and obesity known as GLP-1 receptor agonists may lower the risk of acute pancreatitis recurrence in people with obesity and those with type 2 diabetes, according to a study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
People under age 50 have a greater risk for heart attack or stroke if they’ve lived with obesity for 10 years, according to industry-sponsored research being presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Having medical conditions linked to obesity does not impact the total weight loss achieved with the anti-obesity medication tirzepatide, according to an industry-supported study being presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
People who have had type 1 diabetes for more than 50 years without kidney complications may still be at substantial risk for heart disease, despite excellent control of blood pressure, cholesterol and blood sugar levels, according to a study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
The type of estrogen in hormonal birth control may influence anxiety-like behaviors, according to data presented by Abigail Hegwood, M.S., from the Prakapenka Lab at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
One year after a prediabetes diagnosis, Asians were more likely to develop diabetes mellitus whereas Black patients were more likely to remain in prediabetes range, highlighting racial disparities in diabetes prevention, according to data presented at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Testosterone appears protective against developing type 2 diabetes in men who are overweight or obese and under age 65, but not in men over that age, according to a study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Prediabetes increases the risk of dying before age 75, particularly due to heart disease, kidney disease and acute diabetic complications, according to a new study presented Saturday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right